32047-69-1

Usage

InChI:InChI=1/C14H12N2O/c1-16-13-9-5-4-8-12(13)15-11-7-3-2-6-10(11)14(16)17/h2-9,15H,1H3

Upstream product

• 5814-41-5 5,10-dihydro-11H-dibenzo[b,e][1,4]-diazepin-11-one 
• 74-88-4 methyl iodide 
• 826991-71-3 2-amino-N-(2-iodo-phenyl)-N-methyl-benzamide 
• 34489-87-7 N-(2-iodo-phenyl)-2-nitro-benzamide 
• 615-43-0 2-iodophenylamine 
• 610-14-0 2-nitrobenzyl chloride 
• 826991-63-3 N-(2-iodo-phenyl)-N-methyl-2-nitro-benzamide 
• 5933-35-7 N-(2-nitrophenyl)anthranilic acid 
• 27696-24-8 2-(2-aminophenylamino)benzoic acid 
• 118-92-3 anthranilic acid 
• 88-73-3 2-Chloronitrobenzene 
• 123-91-1 1,4-dioxane 
• 95-54-5 1,2-diamino-benzene 
• 1829-28-3 ethyl 2-iodobenzoate 

Relevant academic research and scientific papers

RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USAGE THEREOF

The present invention discloses a receptor inhibitor of formula (I), a composition comprising the same and the usage thereof.

SULFONAMIDES DERIVED FROM TRICYCLYL-2-AMINOCYCLOALKANOLS AS ANTICANCER AGENTS

A genus of arylsulfonamide derivatives of aminocycloalkanols is disclosed. The compounds are of the following genus (I):. The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.

Palladium-mediated approach to dibenzo[b,e][1,4]diazepines and benzopyrido-analogues. An efficient synthesis of tarpane

An original synthetic route toward dibenzo[b,e][1,4]diazepin-11-ones and analogues pyridobenzodiazepinones has been developed. The method relies upon an intramolecular amination process between an (hetero)aryl halide and the appropriate aniline moiety. Graphical Abstract.

3-piperidyl-4-oxoquinazoline derivatives and pharmaceutical compositions comprising the same

3-piperidyl-4-oxoquinazoline derivatives are provided, which is represented by the formula (I): wherein R represents an amino group or a cyclic amino group such as dibenzoazepine, each of which is substituted with a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, or the like, n is an integer of 1 to 3, R3and R4independently represents a hydrogen atom, a lower alkyl group, or the like, or a pharmaceutically acceptable salt thereof. Compounds (I) of the present invention have excellent MTP-inhibitory activity. Thus, these compounds not only inhibit formation of LDL that is a cause of arteriosclerotic diseases but also regulate TG, cholesterol, and lipoproteins such as LDL in the blood and regulate cellular lipids through regulation of MTP activity. They can also be used as a new type of preventive or therapeutic agents for hyperlipemia or arteriosclerotic diseases. Furthermore, they can be used as therapeutic or preventive agents for pancreatitis, obesity, hypercholesterolemia, and hypertriglyceridemia.

Method of reducing blood glucose

The present invention relates to the use of compounds of the general formula STR1 for reducing blood glucose and/or inhibit the secretion, circulation or effect of insulin antagonizing peptides like CGRP or amylin. Hence the compound can be used in the treatment of insulin resistance related to NIDDM (non-insulin-dependent diabetes mellitus) or aging.

N-substituted azaheterocyclic carboxylic acids and esters thereof

The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.